Therapy Detail

Therapy Name Busulfan + Melphalan
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Busulfan Busulfex Busulphan Busulfex (busulfan) inhibits DNA replication and RNA transcription, likely through induction of DNA alkylation (PMID: 27481448). Busulfex (busulfan) in combination with cyclophosphamide is FDA approved as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for patients with chronic myelogenous leukemia (FDA.gov).
Melphalan Alkeran Chemotherapy - Alkylating 14 Alkeran (melphalan) is an antineoplastic alkylating agent, which cross-links DNA and induces cell toxicity (NCI Drug Dictionary). Alkeran (melphalan) is FDA approved for multiple myeloma and epithelial ovarian carcinoma (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT01175356 Phase I Busulfan + Melphalan Cyclophosphamide + Topotecan 131I-MIBG Cyclophosphamide + Doxorubicin + Vincristine Cisplatin + Etoposide Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin Completed
NCT02506959 Phase II Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Recruiting
NCT00084695 Phase II Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status
NCT01857934 Phase II Doxorubicin Sargramostim Aldesleukin Vincristine Filgrastim Tretinoin Levetiracetam Cisplatin + Etoposide Hu14.18K322A Busulfan + Melphalan Cyclophosphamide + Topotecan Therapy for Children With Advanced Stage Neuroblastoma Recruiting
NCT00020566 Phase III Busulfan + Melphalan Dactinomycin + Doxorubicin + Etoposide + Ifosfamide + Vincristine Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status
NCT01983969 Phase Ib/II Rituximab Dexamethasone Busulfan + Melphalan Azacitidine + Gemcitabine + Vorinostat Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed
NCT02589145 Phase Ib/II Lenalidomide Pyridoxine Dexamethasone Busulfan + Melphalan Enoxaparin Rituximab Gemcitabine Vorinostat Palifermin Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype Terminated
NCT01505569 Phase I Filgrastim Busulfan + Melphalan Etoposide + Ifosfamide Thiotepa Carboplatin Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting